在癌症患者中，糖皮质激素的使用非常广泛，包括治疗与癌症相关的症状，也包括处理抗肿瘤治疗的最常见副作用或免疫系统相关的不良事件。有大量实验证据表明癌细胞具有免疫原性。然而，抗癌T细胞反应的有效激活主要依赖于由专业的抗原递呈细胞（如树突状细胞）进行的高效抗原呈递。改善炎症的医疗管理的经典策略旨在加剧宿主的免疫反应。尽管在治疗许多疾病方面取得了成功，这些药物的疗效有限，而且变异反应可能导致不可预测的结果。理想的疗法应该在不引起免疫抑制的情况下减轻炎症，这对医疗人员来说仍然是一个挑战。 © 2023. 作者，独家许可给斯普林格科学+商务传媒有限责任公司，斯普林格自然的一部分。

The use of glucocorticoids is very varied in the context of cancer patients and includes the treatment of symptoms related to cancer, but also the management of the most common side effects of antitumor treatments or adverse events related to the immune system. There is a quantity of experimental evidence demonstrating that cancer cells are immunogenic. However, the effective activation of anticancer T cell responses closely depends on an efficient antigen presentation carried out by professional antigen-presenting cells such as dendritic cells (DCs). The classic strategies to improve the medical management of inflammation are aimed at exacerbating the host's immune response. Although successful in treating a number of diseases, these drugs have limited efficacy and variable responses can lead to unpredictable results. The ideal therapy should reduce inflammation without inducing immunosuppression and remains a challenge for healthcare personnel.© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.